| 2.94 -0.02 (-0.68%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.79 | 1-year : | 4.21 |
| Resists | First : | 3.25 | Second : | 3.6 |
| Pivot price | 3.08  |
|||
| Supports | First : | 2.67 | Second : | 2.22 |
| MAs | MA(5) : | 3.09 |
MA(20) : | 3.14 |
| MA(100) : | 4.13 |
MA(250) : | 5.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.7 |
D(3) : | 46.9 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 9.44 | Low : | 2.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XBIT ] has closed above bottom band by 24.0%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.1 - 3.12 | 3.12 - 3.13 |
| Low: | 2.88 - 2.9 | 2.9 - 2.92 |
| Close: | 2.91 - 2.94 | 2.94 - 2.97 |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Mon, 14 Apr 2025
XBiotech (NASDAQ:XBIT) Shares Pass Above Fifty Day Moving Average - Here's Why - MarketBeat
Sun, 13 Apr 2025
XBiotech Inc. (NASDAQ:XBIT) Shares Sold by American Century Companies Inc. - Defense World
Sat, 29 Mar 2025
Bank of New York Mellon Corp Has $360,000 Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
Wed, 22 Jan 2025
Barclays PLC Boosts Stock Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
Mon, 13 Jan 2025
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Mon, 30 Dec 2024
XBiotech (NASDAQ:XBIT) Has Debt But No Earnings; Should You Worry? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 35.1 (%) |
| Held by Institutions | 15.7 (%) |
| Shares Short | 800 (K) |
| Shares Short P.Month | 913 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12.5 % |
| Return on Equity (ttm) | -19.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -2.34 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.9 |
| Dividend | 2.5 |
| Forward Dividend | 0 |
| Dividend Yield | 85% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|